532305 Stock Overview
Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and advanced intermediates in India.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Ind-Swift Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹123.16 |
| 52 Week High | ₹138.25 |
| 52 Week Low | ₹63.40 |
| Beta | 0.14 |
| 1 Month Change | 22.85% |
| 3 Month Change | 18.14% |
| 1 Year Change | 90.18% |
| 3 Year Change | 44.81% |
| 5 Year Change | 235.59% |
| Change since IPO | -27.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| 532305 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 1.8% | -0.5% | 1.4% |
| 1Y | 90.2% | 55.3% | 46.1% |
Return vs Industry: 532305 exceeded the Indian Pharmaceuticals industry which returned 55.3% over the past year.
Return vs Market: 532305 exceeded the Indian Market which returned 46.1% over the past year.
Price Volatility
| 532305 volatility | |
|---|---|
| 532305 Average Weekly Movement | 8.2% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 532305 has not had significant price volatility in the past 3 months.
Volatility Over Time: 532305's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 1,496 | n/a | www.indswiftlabs.com |
Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and advanced intermediates in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, and antineoplastic, as well as various products for ADHD symptoms. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services.
Ind-Swift Laboratories Limited Fundamentals Summary
| 532305 fundamental statistics | |
|---|---|
| Market cap | ₹7.27b |
| Earnings (TTM) | ₹431.95m |
| Revenue (TTM) | ₹12.00b |
16.8x
P/E Ratio0.6x
P/S RatioIs 532305 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 532305 income statement (TTM) | |
|---|---|
| Revenue | ₹12.00b |
| Cost of Revenue | ₹6.25b |
| Gross Profit | ₹5.76b |
| Other Expenses | ₹5.33b |
| Earnings | ₹431.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.31 |
| Gross Margin | 47.97% |
| Net Profit Margin | 3.60% |
| Debt/Equity Ratio | 109.8% |
How did 532305 perform over the long term?
See historical performance and comparison